Chronic Obstructive Pulmonary Disease without CC/MCC DRG Reimbursement

DRG 192 addresses inpatient stays for chronic obstructive pulmonary disease without Major Complication or Comorbidity and without Complication or Comorbidity; it defines the clinical scope as uncomplicated chronic obstructive pulmonary disease admissions. This matters for inpatient reimbursement because it sets the standardized Medicare payment for these cases and hinges on precise documentation and coding.

DRG 192 Overview

DRG 192 covers inpatient admissions for patients primarily treated for chronic obstructive pulmonary disease without a Major Complication or Comorbidity and without a Complication or Comorbidity. This Diagnosis-Related Group groups cases with similar clinical complexity and resource use for Medicare payment. It matters for Medicare payment because it determines the base prospective payment amount for the inpatient stay and influences hospital reimbursement and coding accuracy. Accurate assignment affects payment neutrality across hospitals and supports appropriate reimbursement for uncomplicated chronic obstructive pulmonary disease care.

Trials evaluating inpatient respiratory support strategies for acute exacerbations of chronic obstructive pulmonary disease (COPD), such as comparisons between noninvasive ventilation modes, timing of escalation to invasive ventilation, or oxygen titration protocols. These studies enroll hospitalized adults with COPD exacerbations without major comorbid complications (the DRG population), focusing on short-term physiologic outcomes, need for ICU transfer, and length of stay. Findings inform clinicians about best practices for stabilizing breathing while minimizing complications and inform payers about interventions that affect resource use and readmission risk.
Comparative effectiveness studies of pharmacologic and care-pathway approaches to reduce exacerbation severity and hospital resource utilization, for example comparing inpatient corticosteroid dosing regimens, antibiotic stewardship strategies, or standardized COPD exacerbation order sets. These trials target typical COPD inpatients without major complications, measuring clinical improvement, hospital LOS, medication adverse events, and postdischarge exacerbation rates. Results are directly relevant to providers designing evidence-based inpatient protocols and to payers evaluating cost-effectiveness and potential to reduce spending tied to recurrent hospitalizations.
Post-discharge and transitional care studies testing interventions to prevent readmission and improve long-term outcomes, such as structured discharge planning, early outpatient follow-up, home health support, smoking cessation programs, and pulmonary rehabilitation referrals initiated at discharge. These pragmatic trials enroll patients discharged after a COPD exacerbation without CC/MCC, assessing 30‑ and 90‑day readmissions, adherence to maintenance therapy, functional status, and health-care utilization. This research helps health systems and payers identify programs that reduce costly readmissions and improve continuity of care for the typical patients represented by this DRG.

Trials evaluating inpatient respiratory support strategies for acute exacerbations of chronic obstructive pulmonary disease (COPD), such as comparisons between noninvasive ventilation modes, timing of escalation to invasive ventilation, or oxygen titration protocols. These studies enroll hospitalized adults with COPD exacerbations without major comorbid complications (the DRG population), focusing on short-term physiologic outcomes, need for ICU transfer, and length of stay. Findings inform clinicians about best practices for stabilizing breathing while minimizing complications and inform payers about interventions that affect resource use and readmission risk.
Comparative effectiveness studies of pharmacologic and care-pathway approaches to reduce exacerbation severity and hospital resource utilization, for example comparing inpatient corticosteroid dosing regimens, antibiotic stewardship strategies, or standardized COPD exacerbation order sets. These trials target typical COPD inpatients without major complications, measuring clinical improvement, hospital LOS, medication adverse events, and postdischarge exacerbation rates. Results are directly relevant to providers designing evidence-based inpatient protocols and to payers evaluating cost-effectiveness and potential to reduce spending tied to recurrent hospitalizations.
Post-discharge and transitional care studies testing interventions to prevent readmission and improve long-term outcomes, such as structured discharge planning, early outpatient follow-up, home health support, smoking cessation programs, and pulmonary rehabilitation referrals initiated at discharge. These pragmatic trials enroll patients discharged after a COPD exacerbation without CC/MCC, assessing 30‑ and 90‑day readmissions, adherence to maintenance therapy, functional status, and health-care utilization. This research helps health systems and payers identify programs that reduce costly readmissions and improve continuity of care for the typical patients represented by this DRG.

OpenPayer

Summary & Overview

Chronic Obstructive Pulmonary Disease without CC/MCC: Inpatient Reimbursement Overview

DRG 192 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes